{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:40Z","timestamp":1787759980402,"version":"build-2784847793"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021138","name":"Lundbeck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate preferences for key attributes of injected or infused preventive migraine treatments and assess heterogeneity in preferences among Canadian participants with migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current treatment options for migraine prevention differ in their attributes, including mode of administration, efficacy, and dosing frequency; preferences for such attributes can vary among patients. With the advent of new therapies, evidence demonstrating patient preferences for injected or infused preventive migraine treatments is necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Canadian adults self\u2010reporting a diagnosis of migraine completed a cross\u2010sectional, internet\u2010based survey that included a discrete choice experiment. Participants were presented with attributes of preventive migraine treatments, including speed of onset, durability of efficacy, mode of administration, administration setting, and dosing frequency. Latent class analysis (LCA) was used to identify subgroups of patients who differed in their treatment preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 200 participants completed the survey. Participants\u2019 treatment preferences were most sensitive to improvements in the durability of effectiveness from \u201cwears off 2\u2009weeks before next dose\u201d to \u201cdoes not wear off before the next dose\u201d (absolute difference in weights\u2009=\u2009|\u22120.95 to 1.07|\u2009=\u20092.02) and improvements from \u201ccranial injections\u201d to \u201cintravenous infusions\u201d (|\u22121.04 to 0.58|\u2009=\u20091.62); participants equally preferred self\u2010injection and intravenous infusion from a health\u2010care provider (mean weight\u2009=\u20090.58 and 0.47, respectively) as a route of administration over cranial injections (mean weight\u2009=\u2009\u22121.04). Three subgroups were identified with LCA: group one (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009103) prioritized fast\u2010acting and durable therapies, group two (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954) expressed aversion to cranial injections, and group three (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200943) favored treatments administered in a health\u2010care provider setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this sample of Canadian adults with migraine, we showed that durability of effectiveness and mode of administration are key attributes influencing patient preferences for preventive migraine treatments; however, certain groups of patients may differ in their treatment priorities. Our results highlight the need for patient\u2013provider discussions regarding treatment attributes and consideration of patients\u2019 preferences when selecting a preventive migraine treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14781","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T01:20:41Z","timestamp":1720574441000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment"],"prefix":"10.1111","volume":"65","author":[{"given":"Joanna K.","family":"Bougie","sequence":"first","affiliation":[{"name":"Lundbeck Canada Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Krupsky","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Pier","family":"Ladouceur","sequence":"additional","affiliation":[{"name":"Lundbeck Canada Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mulvihill","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"issue":"6","key":"e_1_2_11_4_1","first-page":"10","article-title":"Prevalence of migraine in the Canadian household population","volume":"25","author":"Ramage\u2010Morin PL","year":"2014","journal-title":"Health Rep"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00196-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.75"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00438-z"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000199"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221607"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1671350"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14476"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14255"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14386"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0813-3"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1612242"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2018.01.011"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X14551638"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_11_24_1","volume-title":"Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research","author":"Orme B","year":"2019"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-011-0201-1"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbz016"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9919773"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:41:41Z","timestamp":1762083701000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/head.14781"],"URL":"https:\/\/doi.org\/10.1111\/head.14781","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2023-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}